Toll Free: 1-888-928-9744

Wilson Disease - Pipeline Review, H2 2016

Published: Dec, 2016 | Pages: 45 | Publisher: Global Markets Direct
Industry: Pharmaceuticals & Healthcare | Report Format: Electronic (PDF)

Wilson Disease - Pipeline Review, H2 2016

Summary

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Wilson Disease - Pipeline Review, H2 2016, provides an overview of the Wilson Disease (Genetic Disorders) pipeline landscape.

Wilson disease is a rare autosomal recessive inherited disorder of copper metabolism that is characterized by excessive deposition of copper in the liver, brain, and other tissues. Symptoms include abdominal pain, jaundice, problems with speech, swallowing and muscle stiffness. Treatment includes chelators and Vitamin E supplements. 

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Wilson Disease - Pipeline Review, H2 2016, provides comprehensive information on the therapeutics under development for Wilson Disease (Genetic Disorders), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Wilson Disease (Genetic Disorders) pipeline guide also reviews of key players involved in therapeutic development for Wilson Disease and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase II, Phase I and Preclinical stages are 1, 1 and 2 respectively. Similarly, the Universities portfolio in Preclinical stages comprises 1 molecules, respectively.

Wilson Disease (Genetic Disorders) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

- The pipeline guide provides a snapshot of the global therapeutic landscape of Wilson Disease (Genetic Disorders).
- The pipeline guide reviews pipeline therapeutics for Wilson Disease (Genetic Disorders) by companies and universities/research institutes based on information derived from company and industry-specific sources. 
- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
- The pipeline guide reviews key companies involved in Wilson Disease (Genetic Disorders) therapeutics and enlists all their major and minor projects.
- The pipeline guide evaluates Wilson Disease (Genetic Disorders) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
- The pipeline guide encapsulates all the dormant and discontinued pipeline projects. 
- The pipeline guide reviews latest news related to pipeline therapeutics for Wilson Disease (Genetic Disorders)

Reasons To Buy

- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
- Find and recognize significant and varied types of therapeutics under development for Wilson Disease (Genetic Disorders).
- Classify potential new clients or partners in the target demographic.
- Develop tactical initiatives by understanding the focus areas of leading companies.
- Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.
- Formulate corrective measures for pipeline projects by understanding Wilson Disease (Genetic Disorders) pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
 Table of Contents
Table of Contents 2 List of Tables 4 List of Figures 4 Introduction 5 Global Markets Direct Report Coverage 5 Wilson Disease Overview 6 Therapeutics Development 7 Pipeline Products for Wilson Disease - Overview 7 Pipeline Products for Wilson Disease - Comparative Analysis 8 Wilson Disease - Therapeutics under Development by Companies 9 Wilson Disease - Therapeutics under Investigation by Universities/Institutes 10 Wilson Disease - Pipeline Products Glance 11 Clinical Stage Products 11 Early Stage Products 12 Wilson Disease - Products under Development by Companies 13 Wilson Disease - Products under Investigation by Universities/Institutes 14 Wilson Disease - Companies Involved in Therapeutics Development 15 Dimension Therapeutics Inc 15 GMP-Orphan SAS 16 Revive Therapeutics Ltd 17 Wilson Therapeutics AB 18 Wilson Disease - Therapeutics Assessment 19 Assessment by Monotherapy Products 19 Assessment by Target 20 Assessment by Mechanism of Action 22 Assessment by Route of Administration 24 Assessment by Molecule Type 25 Drug Profiles 27 DTX-701 - Drug Profile 27 Product Description 27 Mechanism Of Action 27 R&D Progress 27 Gene Therapy to Activate ATP7B for Wilson's Disease - Drug Profile 28 Product Description 28 Mechanism Of Action 28 R&D Progress 28 REV-005 - Drug Profile 29 Product Description 29 Mechanism Of Action 29 R&D Progress 29 trientine tetrahydrochloride - Drug Profile 30 Product Description 30 Mechanism Of Action 30 R&D Progress 30 WTX-101 - Drug Profile 31 Product Description 31 Mechanism Of Action 31 R&D Progress 31 Wilson Disease - Dormant Projects 34 Wilson Disease - Discontinued Products 35 Wilson Disease - Product Development Milestones 36 Featured News & Press Releases 36 Dec 05, 2016: Kadmon Submits Abbreviated New Drug Application Filing for Trientine Hydrochloride to FDA 36 Dec 05, 2016: Wilson Therapeutics Announces That WTX101 Meets The Primary Endpoint In Phase 2 Study In Wilson Disease 36 Nov 11, 2016: Wilson Therapeutics Presents Updated Preliminary Clinical Data on WTX101 at the AASLD Liver Meeting 37 Jun 23, 2016: Wilson Therapeutics Presents Preliminary Clinical Data on Decuprate at the 20th International Congress of Parkinson's Disease and Movement Disorders 38 May 30, 2016: Wilson Therapeutics Presents Encouraging Clinical Data On Decuprate At The Congress Of The European Academy Of Neurology 39 May 18, 2016: Wilson Therapeutics Announces That the Ongoing Phase II Study Has Been Fully Enrolled 40 Apr 14, 2016: Wilson Therapeutics presents data on Decuprate (WTX101) from ongoing Phase 2 study at The International Liver Congress 2016 40 Apr 16, 2015: Wilson Therapeutics Announces Presentation Of WTX101-201 Phase 2 Study At The EASL 50th International Liver Congress 2015 41 Nov 17, 2014: Wilson Therapeutics Announces Start Of Phase 2 Study To Evaluate The Efficacy And Safety Of WTX101 In Newly Diagnosed Wilson Disease Patients 42 Jan 13, 2014: Wilson Therapeutics Announces Successful Filing of U.S. IND to Advance WTX101 Development Program for Wilson Disease 42 Appendix 44 Methodology 44 Coverage 44 Secondary Research 44 Primary Research 44 Expert Panel Validation 44 Contact Us 44 Disclaimer 45
List of Tables
Number of Products under Development for Wilson Disease, H2 2016 7 Number of Products under Development for Wilson Disease - Comparative Analysis, H2 2016 8 Number of Products under Development by Companies, H2 2016 9 Number of Products under Investigation by Universities/Institutes, H2 2016 10 Comparative Analysis by Clinical Stage Development, H2 2016 11 Comparative Analysis by Early Stage Development, H2 2016 12 Products under Development by Companies, H2 2016 13 Products under Investigation by Universities/Institutes, H2 2016 14 Wilson Disease - Pipeline by Dimension Therapeutics Inc, H2 2016 15 Wilson Disease - Pipeline by GMP-Orphan SAS, H2 2016 16 Wilson Disease - Pipeline by Revive Therapeutics Ltd, H2 2016 17 Wilson Disease - Pipeline by Wilson Therapeutics AB, H2 2016 18 Assessment by Monotherapy Products, H2 2016 19 Number of Products by Stage and Target, H2 2016 21 Number of Products by Stage and Mechanism of Action, H2 2016 23 Number of Products by Stage and Route of Administration, H2 2016 24 Number of Products by Stage and Molecule Type, H2 2016 26 Wilson Disease - Dormant Projects, H2 2016 34 Wilson Disease - Discontinued Products, H2 2016 35



To request a free sample copy of this report, please complete the form below.

We never share your personal data. Privacy policy
Interested in this report? Get your FREE sample now! Get a Free Sample
Choose License Type
Single User - US $2000
Multi User - US $4000
Hexareeasearch Know

Did you know?

Research Assistance

Phone: 1-415-349-0054

Toll Free: 1-888-928-9744

Email: [email protected]

Why to buy from us

Custom research service

Speak to the report author to design an exclusive study to serve your research needs.

Information security

Your personal and confidential information is safe and secure.

verify